Kunming Pharmaceutical Group Co., Ltd. (referred to as Kunming Pharmaceutical 600422 SH) was established in March 1951. It is a national key high-tech enterprise and one of the top 50 enterprises in China's pharmaceutical industry. With profound professional pharmaceutical experience, its brands such as Luotai, Tianxuanqing, Artemedine, Artem and Arco are well-known at home and abroad; it was listed on the Shanghai Stock Exchange in December 2000. Kunming Pharmaceutical integrates drug research and development, production, sales, commercial wholesale and international marketing, forming a business structure that focuses on independent natural botanical medicines and covers the fields of traditional Chinese medicine, chemical medicine and pharmaceutical circulation; it has 4 subsidiaries: Kunming Traditional Chinese Medicine Factory Co., Ltd. · Yunnan Jintide Panax Notoginseng Industrial Co., Ltd. · Xishuangbanna Banna Pharmaceutical Co., Ltd. · Kunming Pharmaceutical Group Pharmaceutical Commercial Co., Ltd., 1 joint venture: · Kunming Baker Norton Pharmaceutical Co., Ltd., 1 manufacturing center, 1 drug Research Institute, 1 postdoctoral workstation. It has total assets of 1.19 billion yuan and more than 3,000 employees, of which 65% are professional and technical personnel. Relying on the rich plant resources in Yunnan, Kunming Pharmaceutical follows the path of internationalization and high-tech industrialization. It is a unique natural medicine R&D and production and operation enterprise in the country. It has developed artemether series, notoginseng series, gastrodin series and special features. There are more than 40 new natural medicine products with advanced levels at home and abroad, including traditional Chinese medicine and characteristic ethnic medicine, and it has 16 national invention patents. The research and development, internationalization and industrialization of Kunming Pharmaceutical's compound artemether won the second prize of the National Science and Technology Progress Award, and the freeze-dried powder injection technical transformation project won the national high-tech industrialization demonstration project. All preparations, dosage forms and APIs produced by Kunming Pharmaceutical have passed the national GMP certification. Among them, the artemether API workshop has passed the quadruple certification of China's national GMP, World Health Organization (WHO) GMP, Australian TGA, and US FDA. After nearly 20 years of international market development, Kunming Pharmaceutical has exported artemether preparations to more than 40 countries and regions around the world, and has maintained the number one export performance of China's single drug preparations for 13 consecutive years. Outstanding R&D strength, rich product variety resources, strong comprehensive manufacturing capabilities, a quality management system in line with international standards, and an international marketing team constitute the core competitive advantages of Kunming Pharmaceutical. In the future development, Kunming Pharmaceutical will take "green medicine and benefit society" as its purpose, rely on Yunnan's natural medicine resources, give full play to the company's core competitive advantages, continue to maintain its leading position in the pharmaceutical industry, and strive to become a leading natural medicine company in the global pharmaceutical industry. A well-known brand and outstanding representative of botanical medicine.